TY - JOUR
T1 - Untreated primary lung and breast cancers
T2 - Correlation between F-18 FDG kinetic rate constants and findings of in vitro studies
AU - Torizuka, Tatsuo
AU - Zasadny, Kenneth R.
AU - Recker, Betty
AU - Wahl, Richard L.
PY - 1998/6
Y1 - 1998/6
N2 - PURPOSE: To compare the kinetic modeling of 2-[fluorine-18]fluoro-2- deoxy-D-glucose (F-18 FDG) between untreated primary lung and untreated primary breast cancers by using position emission tomographic (PET) findings and to correlate the findings with findings of in vitro studies. MATERIALS AND METHODS: Nineteen patients (12 men, seven women; age range, 49-82 years) with untreated primary lung cancer and 17 women with untreated primary breast cancer (age range, 26-65 years) underwent 1-hour dynamic F-18 FDG PET. A three-compartment model was applied to F-18 FDG kinetics in tumors. The standard uptake value normalized for lean body mass (SUV(lean)) in tumors was measured 50-60 minutes after tracer injection. In vitro, thin-layer chromatography was performed to evaluate the intracellular phosphorylation of tritiated F-18 FDG in human lung cancer and breast cancer cell lines. RESULTS: At PEt, lung cancer had a significantly (P < .003) higher rate constant for F-18 FDG phosphorylation (k3) and SUV(lean) than did breast cancer (0.161 ± 0.150 [standard deviation] vs 0.043 ± 0.018 and 8.25 ± 3.28 vs 3.17 ± 1.08, respectively). Breast cancer showed a significant correlation between k3 and SUV(lean) (r = .607, P < .01), although no such correlation was observed in lung cancer. In vitro studies showed phosphorylation of F-18 FDG in breast cancer cells was less complete in hyperglycemia than it was in lung cancer cells. CONCLUSION: A much lower k3 appears to be a rate-limiting factor for F-18 FDG accumulation in breast cancer, while the higher k3 in lung cancer is probably not rate limiting for F-18 FDG accumulation.
AB - PURPOSE: To compare the kinetic modeling of 2-[fluorine-18]fluoro-2- deoxy-D-glucose (F-18 FDG) between untreated primary lung and untreated primary breast cancers by using position emission tomographic (PET) findings and to correlate the findings with findings of in vitro studies. MATERIALS AND METHODS: Nineteen patients (12 men, seven women; age range, 49-82 years) with untreated primary lung cancer and 17 women with untreated primary breast cancer (age range, 26-65 years) underwent 1-hour dynamic F-18 FDG PET. A three-compartment model was applied to F-18 FDG kinetics in tumors. The standard uptake value normalized for lean body mass (SUV(lean)) in tumors was measured 50-60 minutes after tracer injection. In vitro, thin-layer chromatography was performed to evaluate the intracellular phosphorylation of tritiated F-18 FDG in human lung cancer and breast cancer cell lines. RESULTS: At PEt, lung cancer had a significantly (P < .003) higher rate constant for F-18 FDG phosphorylation (k3) and SUV(lean) than did breast cancer (0.161 ± 0.150 [standard deviation] vs 0.043 ± 0.018 and 8.25 ± 3.28 vs 3.17 ± 1.08, respectively). Breast cancer showed a significant correlation between k3 and SUV(lean) (r = .607, P < .01), although no such correlation was observed in lung cancer. In vitro studies showed phosphorylation of F-18 FDG in breast cancer cells was less complete in hyperglycemia than it was in lung cancer cells. CONCLUSION: A much lower k3 appears to be a rate-limiting factor for F-18 FDG accumulation in breast cancer, while the higher k3 in lung cancer is probably not rate limiting for F-18 FDG accumulation.
KW - Breast neoplasms, emission CT (ECT), 00.12163
KW - Breast neoplasms, radionuclide studies, 00.12163, 00.30
KW - Flourine
KW - LUng neoplasms, emission CT (ECT), 60.12163
KW - Lung neoplasms, radionuclide studies, 60.12163, 60.30
UR - http://www.scopus.com/inward/record.url?scp=0031813987&partnerID=8YFLogxK
U2 - 10.1148/radiology.207.3.9609902
DO - 10.1148/radiology.207.3.9609902
M3 - Article
C2 - 9609902
AN - SCOPUS:0031813987
SN - 0033-8419
VL - 207
SP - 767
EP - 774
JO - Radiology
JF - Radiology
IS - 3
ER -